Pfizer, which supplies Prevenar-13, pneumococcal vaccine that ranks overwhelmingly at the top of the domestic market, is also working hard to introduce the next-generation vaccine.

It started clinical trials for East Asians to introduce Prevenar-20, which was approved by the U.S. Food and Drug Administration (FDA) in June. Prevenar-20 has a preventive effect on seven additional pneumonia streptococcus aureus serotype in Prevenar-13.

Pfizer Korea received approval from the MFDS on the 30th of last month for phase 3 for PF-06482077. It is a candidate for the 20-valent pneumococcal vaccine developed by Pfizer.

On June 8, the U.S. FDA approved the product name Prevenar